#RTI
Right to Inhalation
Because every patient — regardless of income — deserves to breathe freely and live fully.
The Invisible Barrier Between Patients and Their Medicine
Across India, millions of people living with asthma and Chronic Obstructive Pulmonary Disease (COPD) have been prescribed dry powder inhalers — the gold standard of respiratory care. Yet a significant number of these patients, particularly in rural and lower-income communities, stop using their inhalers the moment their acute symptoms subside. The reason is neither ignorance nor indifference. It is simply the price.
A single high-strength combination inhaler — the kind that cardiologists and pulmonologists routinely prescribe for long-term disease management — can cost upwards of ₹391 per unit on the open market. For a daily agricultural worker, a migrant labourer, or a village family living on a modest income, that price point is not just high — it is prohibitive. It forces patients to make an impossible choice: buy medicine or buy food.
This is the silent crisis that Bayu Healthcare's #RTI — Right to Inhalation campaign was born to address. It is not merely a pricing initiative. It is a declaration that access to life-sustaining respiratory treatment is a fundamental right, not a privilege reserved for those who can afford it.
"Access to life-sustaining respiratory treatment must be a fundamental right — not a privilege of income."
Understanding the Disease Burden: Asthma & COPD in India
Asthma and COPD together constitute one of the most significant non-communicable disease burdens in India. Asthma affects an estimated 30 million people across the country, while COPD — largely driven by indoor air pollution, occupational exposure to dust, and tobacco use — affects tens of millions more, particularly in rural areas where biomass cooking fuels remain common.
Despite the scale of this crisis, inhaler penetration in India remains strikingly low compared to global averages. Studies consistently point to cost as the primary driver of non-adherence. When patients cannot afford to refill their inhalers, they rely on rescue medications, suffer preventable exacerbations, make repeated emergency hospital visits, and in many cases, experience permanent decline in lung function.
The recommended treatment for moderate-to-severe asthma and COPD involves a combination of a Long-Acting Beta-2 Agonist (LABA) and an Inhaled Corticosteroid (ICS). These two components work synergistically — the LABA opens up the airways while the ICS reduces chronic inflammation. Taken together, regularly and consistently, they dramatically reduce the frequency of attacks, hospitalisations, and the risk of fatal exacerbations.
But "regularly and consistently" demands financial consistency. This is precisely where most low-income patients fall through the gap.
in India
for high-strength DPI
by Bayu Healthcare
living normal lives
The Science Behind the Solution: What Makes LABA+ICS Critical
To fully appreciate why the #RTI initiative matters, it helps to understand the clinical science it is grounded in. Asthma and COPD are both diseases of chronic airway inflammation and obstruction — but they are not identical, and their long-term management requires specific pharmacological precision.
Formoterol Fumarate: The Long-Acting Bronchodilator
Formoterol is a LABA — a Long-Acting Beta-2 Agonist — that works by binding to beta-2 adrenergic receptors in bronchial smooth muscle, causing relaxation and dilation of the airways. Unlike short-acting bronchodilators that provide quick relief for 4–6 hours, Formoterol maintains airway opening for up to 12 hours, making it ideal for twice-daily dosing as part of maintenance therapy. Its relatively rapid onset also makes it uniquely useful in acute situations compared to other LABAs.
Budesonide: The Inhaled Corticosteroid
Budesonide is an inhaled corticosteroid (ICS) that acts locally in the airways to suppress the chronic inflammatory response that underlies both asthma and COPD. By reducing mucosal inflammation, airway hyperresponsiveness, and mucus secretion, Budesonide addresses the root cause of disease progression — not just the symptoms. It is one of the most evidence-backed ICS molecules in global respiratory medicine.
The Combination Advantage
Used together, Formoterol and Budesonide in a single dry powder inhaler (DPI) offer a synergistic benefit that exceeds the sum of either drug alone. Clinical evidence supports their combination for reducing exacerbation frequency, improving lung function scores (FEV1), lowering systemic corticosteroid use, and significantly improving patient quality of life. Global guidelines from GINA (Global Initiative for Asthma) and GOLD (Global Initiative for Chronic Obstructive Lung Disease) endorse LABA+ICS combinations as standard of care for patients requiring Step 3 and above treatment.
Clinical evidence supports that LABA+ICS combinations reduce hospitalisation rates, exacerbation frequency, and measurably improve quality of life — if patients can access and afford them consistently.
Fabhale: India's Most Accessible Combination DPI
The cornerstone of the #RTI initiative is Fabhale — Bayu Healthcare's flagship dry powder inhaler that combines Formoterol Fumarate Dihydrate 6 mcg with Budesonide, available in two clinically relevant strengths:
Fabhale 200 delivers Formoterol 6 mcg + Budesonide IP 200 mcg, and Fabhale 400 delivers Formoterol 6 mcg + Budesonide IP 400 mcg. These strengths align precisely with international dosing protocols for mild-to-moderate and moderate-to-severe disease respectively.
What sets Fabhale apart in the Indian respiratory landscape is not the formulation — it is the price. Fabhale 400, comparable in composition to competitor products retailing at ₹391, is available at just ₹150. Fabhale 200 is priced at ₹99. These are not subsidised, donor-funded prices. They represent Bayu Healthcare's commitment to manufacturing efficiency, fair margins, and a mission-driven pricing philosophy that puts patients first.
The Fabhale Range
World-class LABA+ICS dry powder inhalers at prices that put long-term therapy within reach of every patient.
Budesonide IP 200 mcg
Budesonide IP 400 mcg
Jai's Story: From Crisis to Continuity
Jai is a village patient whose story is emblematic of millions across rural India. After a severe respiratory episode, his doctor prescribed a combination LABA+ICS inhaler — the right clinical decision. Jai was instructed to use the inhaler regularly, not just when breathless.
The problem was the price. The high-strength competitor inhaler was priced at ₹391. Once Jai's acute symptoms eased, the cost became impossible to justify against his household budget. He stopped. And so began a cycle that is heartbreakingly common: symptoms return, emergency care follows, brief relief is found, medication is abandoned, and the cycle repeats. A life half-lived, punctuated by crises.
That cycle was broken when #RTI launched. Jai was introduced to Fabhale 400 — the same clinical strength, a fraction of the cost. For three years now, Jai has been on continuous Fabhale therapy. He has not missed a dose because of cost. He has not been hospitalised. He works. He is present for his family. He breathes freely.
"Like Jai, there are thousands of patients now living normal lives because of #RTI. But there are still lakhs of patients who still cannot afford regular inhalation therapy."
The #RTI Movement: More Than a Product
What began as a pricing decision has grown into a movement. The #RTI — Right to Inhalation campaign is founded on a simple but radical premise: that chronic respiratory disease management is not a luxury. That a patient in a village in Uttar Pradesh deserves the same quality of maintenance therapy as a patient in a Mumbai high-rise. That the gap between what doctors prescribe and what patients can afford must be closed — not by cutting clinical corners, but by rethinking the economics of healthcare delivery.
The Bayu Healthcare portfolio now includes four world-class dry powder inhalers — Fabhale 200, Fabhale 400, Uphale, and Uphale Plus — each positioned as among the most economical DPIs available anywhere in the world. These are not stripped-down alternatives. They are full-formulation, clinically validated inhalers manufactured to the same standards as their higher-priced competitors.
The campaign also recognises that price alone is not enough. Consistent access requires awareness, prescription, and community trust. This is why #RTI actively works with doctors, pharmacists, healthcare workers, and community health volunteers across India — building the human infrastructure that ensures patients not only have access to affordable inhalers, but understand why using them every day is the path to a genuinely normal life.
The Role of Doctors and Healthcare Providers
The physician community is central to the success of #RTI. Prescribing the right molecule at the right dose is, of course, the foundation. But in the context of lower-income patients, prescribing must be accompanied by an awareness of affordability. A prescription that the patient cannot fill does not heal anyone.
Bayu Healthcare invites every doctor and healthcare provider to become an active partner in the #RTI initiative. This means:
Prescribing with access in mind. When a patient presents with asthma or COPD and financial constraints are a known factor, choosing Fabhale over a higher-priced equivalent is a clinical act of equity. The molecule is the same. The outcome, when adherence is sustained, is demonstrably better.
Counselling for long-term adherence. Many patients stop inhalers once symptoms improve, not understanding that asthma and COPD require continuous management even in asymptomatic periods. Physicians who take three minutes to explain the maintenance versus rescue distinction can change a patient's adherence trajectory permanently.
Extending the reach. Through ASHA workers, rural health camps, telemedicine consultations, and community pharmacies, the #RTI message can travel far beyond urban hospitals. Bayu Healthcare is committed to supporting healthcare providers in building these last-mile distribution channels.
"We request all doctors and healthcare providers to help us in this initiative. Please support #RTI — Right to Inhalation."
The Broader Vision: Inhalation Equity Across India
India's respiratory health challenge is immense, but it is not intractable. The clinical tools exist. The pharmacological evidence is established. The manufacturing capacity is available. What has been missing — and what #RTI is working to supply — is the will to make those tools available at a price that does not discriminate by postcode or income.
Thousands of patients like Jai have already crossed to the other side of that divide. They are living proof that when affordability is resolved, adherence follows, and when adherence follows, outcomes improve. This is not theory. It is three years of data, lived experience, and changed lives unfolding across India's villages and towns.
But the task is far from complete. There are lakhs — hundreds of thousands — of patients still caught in the same cycle that once trapped Jai. Patients whose doctors have written the right prescription, whose lungs need the right treatment, but whose wallets have drawn an invisible line between them and their health.
#RTI exists to erase that line.
If you are a doctor, join us. If you are a pharmacist, stock our inhalers. If you are a healthcare worker, share this story. And if you are a patient — know that your right to breathe freely, to live without the fear of your next attack, to be present and whole for the people you love — that right is not beyond your reach.
#RTI #RightToInhalation #BayuHealthcare
Join the #RTI Movement
Support the Right to Inhalation. Help us bring affordable, effective respiratory care to every patient across India — regardless of income.
Support #RTI Initiative